Literature DB >> 25650893

Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma.

Ilan Ben-Shabat1, Christoffer Hansson2, Malin Sternby Eilard3, Christian Cahlin3, Magnus Rizell3, Per Lindnér3, Jan Mattsson1, Roger Olofsson Bagge4.   

Abstract

Isolated hepatic perfusion (IHP) is a procedure where the liver is surgically isolated and perfused with a high concentration of the chemotherapeutic agent melphalan. Briefly, the procedure starts with the setup of a percutaneous veno-venous bypass from the femoral vein to the external jugular vein. Via a laparotomy, catheters are then inserted into the proper hepatic artery and the caval vein. The portal vein and the caval vein, both supra- and infrahepatically, are then clamped. The arterial and venous catheters are connected to a heart lung machine and the liver is perfused with melphalan (1 mg/kg body weight) for 60 min. This way it is possible to locally perfuse the liver with a high dose of a chemotherapeutic agent, without leakage to the systemic circulation. In previous studies including patients with isolated liver metastases of uveal melanoma, an overall response rate of 33-100% and a median survival between 9 and 13 months, have been reported. The aim of this protocol is to give a clear description of how to perform the procedure and to discuss IHP as a treatment option for liver metastases of uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25650893      PMCID: PMC4354564          DOI: 10.3791/52490

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  30 in total

1.  Isolated perfusion of the liver with HN2.

Authors:  R K AUSMAN; J B AUST
Journal:  Surg Forum       Date:  1960

Review 2.  Hepatic surgical anatomy.

Authors:  John E Skandalakis; Lee J Skandalakis; Panajiotis N Skandalakis; Petros Mirilas
Journal:  Surg Clin North Am       Date:  2004-04       Impact factor: 2.741

Review 3.  Insertion and management of percutaneous veno-venous bypass cannula for liver transplantation: a reference for transplant anesthesiologists.

Authors:  Tetsuro Sakai; Silviu Gligor; John Diulus; Richard McAffee; J Wallis Marsh; Raymond M Planinsic
Journal:  Clin Transplant       Date:  2010 Sep-Oct       Impact factor: 2.863

4.  Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.

Authors:  T Kivelä; S Suciu; J Hansson; W H J Kruit; M-S Vuoristo; O Kloke; M Gore; M Hahka-Kemppinen; L-M Parvinen; E Kumpulainen; Y Humblet; S Pyrhönen
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

5.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

6.  Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs.

Authors:  W C Barker; M P Andrich; H R Alexander; D L Fraker
Journal:  Eur J Nucl Med       Date:  1995-11

7.  Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Authors:  S Leyvraz; S Piperno-Neumann; S Suciu; J F Baurain; M Zdzienicki; A Testori; E Marshall; M Scheulen; T Jouary; S Negrier; J B Vermorken; E Kaempgen; X Durando; D Schadendorf; R Karra Gurunath; U Keilholz
Journal:  Ann Oncol       Date:  2014-02-07       Impact factor: 32.976

Review 8.  Anesthetic considerations during liver surgery.

Authors:  Imre Redai; Jean Emond; Tricia Brentjens
Journal:  Surg Clin North Am       Date:  2004-04       Impact factor: 2.741

9.  Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.

Authors:  R Olofsson; C Cahlin; C All-Ericsson; F Hashimi; J Mattsson; M Rizell; P Lindnér
Journal:  Ann Surg Oncol       Date:  2013-10-19       Impact factor: 5.344

Review 10.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22
View more
  1 in total

1.  Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver.

Authors:  Eleonora M de Leede; Mark C Burgmans; Christian H Martini; Fred G J Tijl; Arian R van Erkel; Jaap Vuyk; Ellen Kapiteijn; Cornelis Verhoef; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  J Vis Exp       Date:  2016-07-31       Impact factor: 1.355

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.